Table 2.
Results of Efficacy.
| Days of follow -up | No of patients positive for gametocytes | Patients sample positive for exflagellation | ||
| Pts treated with PQ N = 31 |
Pts treated with BQ N = 59 |
Pts treated with PQ N = 31 |
Pts treated with BQ N = 59 |
|
| 1 | 31/31 100% |
59/59 100% |
31/31 100% |
59/59 100% |
| 4 | 31/31 100% |
59/59 100% |
31/31 100% |
59/59 100% |
| 8 | 20/31 * 65% |
19/59 * 32% |
16/31 * 52% |
7/59 * 12% |
| 15 | Nil | Nil | Nil | Nil |
| 22 | Nil | Nil | Nil | Nil |
| 29 | Nil | Nil | Nil | Nil |
* statistically significant P < 0.05
Acknowledgements: This study was carried out as a project under the Center for Advanced Research in Clinical Pharmacology, and was funded by the Indian Council of Medical Research, New Delhi. We thank Nicholas Piramal India Ltd for the supply of bulaquine capsules.